Laddar...
Potentiators of Defective ΔF508–CFTR Gating that Do Not Interfere with Corrector Action
Combination drug therapies under development for cystic fibrosis caused by the ∆F508 mutation in cystic fibrosis transmembrane conductance regulator (CFTR) include a “corrector” to improve its cellular processing and a “potentiator” to improve its chloride channel function. Recently, it was reported...
Sparad:
| I publikationen: | Mol Pharmacol |
|---|---|
| Huvudupphovsmän: | , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
The American Society for Pharmacology and Experimental Therapeutics
2015
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4576684/ https://ncbi.nlm.nih.gov/pubmed/26245207 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.115.099689 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|